📊 KEQU Key Takeaways
Is Kewaunee Scientific Corp. /DE/ (KEQU) a Good Investment?
Kewaunee Scientific exhibits strong revenue growth (+17.3% YoY) and maintains robust financial health with low leverage (0.27x debt/equity) and positive free cash flow, but profitability deterioration is concerning—net income declined 9.7% YoY despite revenue gains, indicating operational efficiency challenges in this low-margin business.
Kewaunee shows strong revenue growth, solid cash conversion, and a healthy balance sheet with ample liquidity and modest leverage. However, declining net income and diluted EPS despite 17.3% revenue growth indicate margin pressure or unfavorable below-operating-line effects, tempering the otherwise positive fundamental outlook.
Kewaunee Scientific Corp. /DE/ Key Strengths (KEQU)
- Strong top-line growth of 17.3% demonstrates market demand for lab equipment
- Fortress balance sheet: 0.27x debt/equity with 2.18x current ratio and $9.9M cash
- Positive free cash flow generation of $14.7M with exceptional interest coverage of 15.8x
- Moderate capital intensity (CapEx of $3.9M) enables cash reinvestment flexibility
- Revenue increased 17.3% year over year to $282.00 million
- Free cash flow of $14.70 million exceeded net income, indicating strong earnings quality
- Healthy liquidity and leverage, with a 2.18x current ratio, 0.27x debt-to-equity ratio, and 15.8x interest coverage
KEQU Stock Risks: Kewaunee Scientific Corp. /DE/ Investment Risks
- Profitability declining sharply (-9.7% net income YoY despite +17.3% revenue growth) signals margin compression and operational deleverage
- Operating margin of 5.9% and net margin of 3.4% are critically low, limiting financial flexibility and downside protection
- Gross margin of 28.5% combined with failing to expand EBIT suggests inability to pass through costs or control operating expenses
- EPS down 15.9% YoY indicates shareholder value destruction despite growth, raising sustainability questions
- Net income declined 9.7% despite strong revenue growth
- Diluted EPS fell 15.9%, more sharply than net income
- Thin 3.4% net margin leaves earnings vulnerable to cost inflation or operating disruption
Key Metrics to Watch
- Gross margin trend and cost of goods sold ratio—verify margin compression is not structural
- Operating expense ratio and operating leverage—confirm cost discipline can be regained
- Free cash flow conversion and working capital management—essential to validate cash generation quality amid profit decline
- Operating and net margin trend
- Free cash flow conversion relative to net income
Kewaunee Scientific Corp. /DE/ (KEQU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.18x current ratio provides a solid financial cushion.
KEQU Profit Margin, ROE & Profitability Analysis
KEQU vs Market Sector: How Kewaunee Scientific Corp. /DE/ Compares
How Kewaunee Scientific Corp. /DE/ compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kewaunee Scientific Corp. /DE/ Stock Overvalued? KEQU Valuation Analysis 2026
Based on fundamental analysis, Kewaunee Scientific Corp. /DE/ has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kewaunee Scientific Corp. /DE/ Balance Sheet: KEQU Debt, Cash & Liquidity
KEQU Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kewaunee Scientific Corp. /DE/'s revenue has grown significantly by 67% over the 5-year period, indicating strong business expansion. The most recent EPS of $3.83 reflects profitable operations.
KEQU Revenue Growth, EPS Growth & YoY Performance
KEQU Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $67.2M | $692.0K | $0.23 |
| Q2 2026 | $47.8M | $2.2M | $0.82 |
| Q1 2026 | $48.4M | $2.2M | $0.74 |
| Q3 2025 | $46.8M | $1.4M | $0.45 |
| Q2 2025 | $47.8M | $2.2M | $0.93 |
| Q1 2025 | $48.4M | $2.2M | $0.74 |
| Q3 2024 | $46.8M | -$243.0K | $-0.09 |
| Q2 2024 | $50.4M | -$243.0K | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kewaunee Scientific Corp. /DE/ Dividends, Buybacks & Capital Allocation
KEQU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kewaunee Scientific Corp. /DE/ (CIK: 0000055529)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jul 7, 2026 | DEF 14A | ny20068820x1_def14a.htm | View → |
| Jul 2, 2026 | 4 | xslF345X06/wk-form4_1783007843.xml | View → |
| Jul 2, 2026 | 4 | xslF345X06/wk-form4_1783007735.xml | View → |
| Jul 2, 2026 | 4 | xslF345X06/wk-form4_1783007628.xml | View → |
| Jul 2, 2026 | 4 | xslF345X06/wk-form4_1783007511.xml | View → |
❓ Frequently Asked Questions about KEQU
What is the AI rating for KEQU?
Kewaunee Scientific Corp. /DE/ (KEQU) has a Combined AI Grade of A from Claude (B) and ChatGPT (A) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KEQU's key strengths?
Claude: Strong top-line growth of 17.3% demonstrates market demand for lab equipment. Fortress balance sheet: 0.27x debt/equity with 2.18x current ratio and $9.9M cash. ChatGPT: Revenue increased 17.3% year over year to $282.00 million. Free cash flow of $14.70 million exceeded net income, indicating strong earnings quality.
What are the risks of investing in KEQU?
Claude: Profitability declining sharply (-9.7% net income YoY despite +17.3% revenue growth) signals margin compression and operational deleverage. Operating margin of 5.9% and net margin of 3.4% are critically low, limiting financial flexibility and downside protection. ChatGPT: Net income declined 9.7% despite strong revenue growth. Diluted EPS fell 15.9%, more sharply than net income.
What is KEQU's revenue and growth?
Kewaunee Scientific Corp. /DE/ reported revenue of $282.0M.
Does KEQU pay dividends?
Kewaunee Scientific Corp. /DE/ does not currently pay dividends.
Where can I find KEQU SEC filings?
Official SEC filings for Kewaunee Scientific Corp. /DE/ (CIK: 0000055529) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KEQU's EPS?
Kewaunee Scientific Corp. /DE/ has a diluted EPS of $3.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KEQU's fundamental grade?
Based on our AI fundamental analysis in August 2026, Kewaunee Scientific Corp. /DE/ has a A grade with 66% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is KEQU stock overvalued or undervalued?
Valuation metrics for KEQU: ROE of 12.9% (sector avg: 15%), net margin of 3.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KEQU's AI grade for 2026?
Our dual AI analysis gives Kewaunee Scientific Corp. /DE/ a combined A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KEQU's free cash flow?
Kewaunee Scientific Corp. /DE/'s operating cash flow is $18.6M, with capital expenditures of $3.9M. FCF margin is 5.2%.
How does KEQU compare to other Market stocks?
Vs Default sector averages: Net margin 3.4% (avg: 12%), ROE 12.9% (avg: 15%), current ratio 2.18 (avg: 1.8).